Markets.com Logo
markets.com

TBIO

$--
--%
1d
1w
1m

Analysis and statistics

  • Open
    --
  • Previous Close
    --
  • 52 Week Change
    --
  • Day Range
    --
  • 52 Week High/Low
    --
  • Dividend Per Share
    --
  • Market cap
    --
  • EPS
    --
  • Beta
    --
  • Volume
    --

About

TBIO.US represents the common stock of Translate Bio, Inc., a company formerly focused on developing messenger RNA (mRNA) therapeutics. Translate Bio was acquired by Sanofi in August 2021. Therefore, TBIO.US is no longer actively traded on the stock market, and its price history reflects its value prior to the acquisition. Prior to its acquisition, Translate Bio focused on developing mRNA therapeutics for various diseases, including cystic fibrosis and liver diseases.
markets.com
Micron vs SanDisk: Which Stock Is Better Positioned for AI Growth?

Micron vs SanDisk: Which Stock Is Better Positioned for AI Growth?

Julian Parker|--
AMD vs Intel vs Arm: Which Stock Could Benefit Most From the AI Inference Boom?

AMD vs Intel vs Arm: Which Stock Could Benefit Most From the AI Inference Boom?

Daniel Carter|--
AMD Joins the $1 Trillion Club as AI Demand Lifts Shares: AI Chip Stock Forecast and Outlook

AMD Joins the $1 Trillion Club as AI Demand Lifts Shares: AI Chip Stock Forecast and Outlook

Julian Parker|--
British Pound Short-Term Outlook: Can GBP/USD Hold 1.33 as Fed–BoE Policy Divergence Widens?

British Pound Short-Term Outlook: Can GBP/USD Hold 1.33 as Fed–BoE Policy Divergence Widens?

Julian Parker|--
Stellar XLM Price Prediction 2026, 2027 & 2030: Can XLM Reach $1?

Stellar XLM Price Prediction 2026, 2027 & 2030: Can XLM Reach $1?

Daniel Carter|--

The energy sector remains a hot topic & precious metals

Darius Anucauskas|--
Dollar to Mexican Peso Forecast 2026–2030: Can USD/MXN Break Above 17.50 as the Rate Gap Narrows?

Dollar to Mexican Peso Forecast 2026–2030: Can USD/MXN Break Above 17.50 as the Rate Gap Narrows?

Julian Parker|--

Factors

Clinical Trial Results: Positive data boosts investor confidence, driving up demand and stock price. Negative results or trial failures often lead to significant price drops.

Regulatory Approvals: FDA approval of TBIO's drugs or therapies is a major catalyst, increasing revenue potential and stock valuation. Rejections or delays can negatively impact the stock.

Market Sentiment: General market trends, investor optimism or pessimism, and the overall health of the biotechnology sector influence TBIO's stock price.

Competition: The presence of competing products or companies in the same therapeutic area can affect TBIO's market share and stock performance.

Financial Performance: Revenue, earnings, and profitability reports impact investor perception of TBIO's value and future growth prospects.

Partnerships and Acquisitions: Collaborations with other companies or potential acquisition targets can lead to increased stock value.

People Also Watch

Latest news

Gold Price Today: Gold Holds Near $4,280 After Strong US PMI Sends Treasury Yields Higher

Gold Price Today: Gold Holds Near $4,280 After Strong US PMI Sends Treasury Yields Higher

Julian Parker|--
McDonald’s Stock Falls Nearly 5% as NEXT Investor Day Raises Turnaround Questions

McDonald’s Stock Falls Nearly 5% as NEXT Investor Day Raises Turnaround Questions

Julian Parker|--
Treasury Yields Spike After Strong US PMI as Nasdaq Falls More Than 1%

Treasury Yields Spike After Strong US PMI as Nasdaq Falls More Than 1%

Julian Parker|--

Latest Education Articles

Risk Management 101

Risk Management 101

Julian Parker|--
Best AI Stocks to Buy Now: 10 Best Performing AI Stocks to Watch in 2026

Best AI Stocks to Buy Now: 10 Best Performing AI Stocks to Watch in 2026

Julian Parker|--
Gold Scalping Strategy: How Scalping XAU/USD Works

Gold Scalping Strategy: How Scalping XAU/USD Works

Julian Parker|--
Recommended Topics
markets.com